We are thrilled to announce the initiation of two groundbreaking clinical trials, marking significant strides in the field of sarcoma research. These trials, Abbisko Pimicotimib and PEAK, hold promise in advancing treatment options for patients facing GIST and TGCT challenges.
Abbisko Pimicotimib Trial: Embarking on a phase III journey, this trial is actively recruiting patients with inoperable TGCT (formerly known as PVNS). The study explores the efficacy of pimicotinib, a novel oral TKI, compared to a placebo, with permitted crossover. This represents a crucial step towards addressing the unique challenges posed by inoperable TGCT.
PEAK Trial: A phase III trial open for enrollment, PEAK focuses on patients with advanced GIST who are progressing or intolerant to imatinib. The trial investigates the combination of sunitinib and bezuclastinib versus sunitinib alone, offering a potential paradigm shift in the management of GIST cases.
We invite all eligible patients to consider participation, and healthcare professionals to reach out for patient enrollment. These trials signify our commitment to advancing sarcoma care, and we look forward to the impactful insights they will undoubtedly yield. Stay tuned for updates as we push the boundaries of sarcoma research.